Aerium Therapeutics was focused on the discovery and development of monoclonal antibodies and antiviral treatments specifically targeting SARS-CoV-2 variants. The company aimed to address the ongoing challenges posed by emerging viral mutations and their impact on public health.
Funding
Funding not disclosed
Founders
Product
Problem
The emergence of SARS-CoV-2 variants poses ongoing challenges to public health, requiring the development of targeted antiviral treatments. Viral mutations can reduce the effectiveness of existing therapies, necessitating continuous research and development of new interventions.
Solution
Aerium Therapeutics focused on the discovery and development of monoclonal antibodies and antiviral treatments specifically targeting SARS-CoV-2 variants. The company aimed to address the challenges posed by emerging viral mutations and their impact on public health. Their research efforts were directed towards creating effective solutions to combat the evolving nature of the virus.
Target Audience
The primary target audience included public health organizations and individuals at risk of SARS-CoV-2 infection.
Features
- Discovery of monoclonal antibodies targeting SARS-CoV-2 variants
- Development of antiviral treatments